Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jul 1;5(7):e2221626.
doi: 10.1001/jamanetworkopen.2022.21626.

Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non-Small Cell Lung Cancer

Affiliations
Observational Study

Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non-Small Cell Lung Cancer

Samilia Obeng-Gyasi et al. JAMA Netw Open. .

Erratum in

  • Error in Byline and Author Affiliations.
    [No authors listed] [No authors listed] JAMA Netw Open. 2023 Mar 1;6(3):e236766. doi: 10.1001/jamanetworkopen.2023.6766. JAMA Netw Open. 2023. PMID: 36930157 Free PMC article. No abstract available.

Abstract

Importance: Adverse social determinants of health (SDHs) (eg, poverty) are associated with poor oncologic outcomes among patients with lung cancer. However, no studies have evaluated biological correlates of adverse SDHs, operationalized as allostatic load (AL), with mortality due to lung cancer.

Objective: To examine the association among AL, SDHs, and mortality among patients with metastatic non-small cell lung cancer (NSCLC).

Design, setting, and participants: This cross-sectional study of an observational cohort was performed at a National Cancer Institute-designated comprehensive cancer center with data accrued from June 1, 2017, to August 31, 2019. Patients with metastatic (stage IV) NSCLC enrolled at diagnosis into a prospective observational cohort study were included in the present analysis if they had all the biomarkers to calculate an AL score (N = 143). Follow-up was completed on August 31, 2021, and data were analyzed from July 1 to September 30, 2021.

Exposures: Social determinants of health.

Main outcomes and measures: Overall mortality and AL.

Results: A total of 143 patients met the study criteria with a median age of 63 (IQR, 55-71) years (89 men [62.2%] and 54 women [37.8%]). In terms of race and ethnicity, 1 patient (0.7%) was Asian, 7 (4.9%) were Black, 117 (81.8%) were White, 17 (11.9%) were of multiple races, and 1 (0.7%) was of other race or ethnicity. The mean (SD) AL was 2.90 (1.37). Elevated AL covaried with lower educational level (r = -0.26; P = .002), male sex (r = 0.19; P = .02), limited mobility (r = 0.19; P = .04), worsening self-care (r = 0.30; P < .001), problems engaging in usual activities (r = 0.21; P = .01), depressive symptoms (r = 0.23; P = .005), and a high number of stressful life events (r = 0.30; P < .001). Multivariable analysis found only increasing difficulty with mobility (r = 0.37 [95% CI, 0.13-0.60]; P = .002) and male sex (r = 0.63 [95% CI, 0.19-1.08]; P = .005) associated with higher AL. On adjusted analysis, elevated AL (hazard ratio, 1.43 [95% CI, 1.16-1.79]; P = .001) and low educational level (hazard ratio, 2.11 [95% CI, 1.03-4.34]; P = .04) were associated with worse overall mortality.

Conclusions and relevance: The findings of this cross-sectional study suggest that higher AL was associated with adverse SDHs and worse overall mortality among patients with advanced NSCLC. These results provide a framework for replication and further studies of AL as a biological correlate for SDH and future prognostic marker.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Presley reported receiving grants from the National Institute on Aging during the conduct of the study. Dr Carbone reported consulting and serving on the advisory boards for AstraZeneca, Eisai Co Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Seattle Genetics Inc, Mirati Therapeutics, and inThought; serving on the advisory boards for Bristol Myers Squibb, Intellisphere (G1 Therapeutics, Inc), Merck & Co Inc, Merck KGgA, G1 Therapeutics Inc, Iovance Biotherapeutics, Jazz Pharmaceuticals PLC, Regeneron Pharmaceuticals Inc, and Sanofi SA; consulting for Boehringer-Ingelheim, Daiichi Sankyo Company Limited, Flame Biosciences, Genentech Inc, NovoCure Limited, Intellisphere (OncLive), OncoCyte Corporation, OncoHost, AbbVie, Caris Life Sciences, Curio Science, Johnson & Johnson, Merck/EMD Serono, and OncLive; having an advisory agreement with Flame Biosciences, Gritstone bio Inc, and Janssen Pharmaceuticals; serving as a speaker for Roche Diagnostics China and Pfizer Inc; and serving as Ask the Expert for Novartis International AG outside the submitted work. Dr Ceppa reported consulting for AstraZeneca annually outside the submitted work. Dr Carlos reported receiving salary support as editor in chief of the Journal of the American College of Radiology outside the submitted work. No other disclosures were reported.

References

    1. Centers for Disease Control and Prevention . An Update on Cancer Deaths in the United States. US Department of Health and Human Services, Centers for Disease Control and Prevention, Division of Cancer Prevention and Control; 2021.
    1. US Cancer Statistics Working Group . Cancer Statistics Data Visualizations Tool, based on 2020 submission data (1999-2018). US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. June 2021. Accessed May 8, 2022. https://www.cdc.gov/cancer/dataviz
    1. Noone AM, Howlader N, Krapcho M, et al, eds. National Cancer Institute. SEER Cancer Statistics Review, 1975-2015, based on November 2017 SEER data submission. Updated September 10, 2018. Accessed May 8, 2022. https://seer.cancer.gov/archive/csr/1975_2015/
    1. Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non–small cell lung cancer. Chest. 2007;132(1):185-192. doi: 10.1378/chest.07-0442 - DOI - PubMed
    1. Namburi N, Timsina L, Ninad N, Ceppa D, Birdas T. The impact of social determinants of health on management of stage I non–small cell lung cancer. Am J Surg. 2021;S0002-9610(21)00614-0. doi: 10.1016/j.amjsurg.2021.10.022 - DOI - PubMed

Publication types